Higher visit-to-visit variability in systolic blood pressure was associated with an increased risk of kidney disease progression in patients with IgA nephropathy (HR 2.12; 95% CI 1.31-3.44).
Cohort (n=1,376)
No
Does higher visit-to-visit variability in systolic blood pressure increase the risk of kidney disease progression in patients with IgA nephropathy?
Higher visit-to-visit variability in systolic blood pressure is significantly associated with an increased risk of kidney disease progression in patients with IgA nephropathy, independent of mean blood pressure.
Hazard Ratio: 2.12 (95% CI 1.31–3.44)
p-value: p=<0.001
ABSTRACT Background The visit-to-visit variability (VVV) in blood pressure (BP) is an important risk factor for stroke and coronary heart disease and may also be associated with kidney damage and the development of chronic kidney disease (CKD). Data on the association between VVV in BP and the risk of CKD progression among patients with immunoglobulin A nephropathy (IgAN) are limited. We aimed to evaluate the relationships of VVV in BP with the progression of IgAN. Methods We assessed 1376 patients with IgAN at Peking University First Hospital. The main VVV in BP was expressed as the standard deviation (SD), coefficient of variation (CV) and average real variability (ARV). The associations of variability in BP with composite kidney disease progression events, defined as a 50% decline in estimated glomerular filtration rate (eGFR) and kidney failure, were examined using Cox models. Results During a median follow-up of 44. 1 months (interquartile range 23. 0–76. 7), 247 (18. 0%) patients experienced composite kidney disease progression events. With a higher SD in systolic BP (SBP) values, the risk of kidney disease progression events increased hazard ratio HR 1. 07 95% confidence interval (CI) 1. 03–1. 11; P. 001 after maximal adjustment, including baseline SBP and mean SBP during the first 12-month period. Using the first quartile of SD SBP values as the reference, the risk of composite kidney disease progression events was higher among patients with higher SD SBP values; the HR was 2. 12 (95% CI 1. 31–3. 44) in the highest quartile (P for trend. 001). A similar trend could be observed when analysing the SD of diastolic BP, but the risk was not significantly increased. The associations were similar when analysed with the CV and ARV. Conclusion SBP variability was significantly associated with kidney disease progression in IgAN.
Tang et al. (Wed,) conducted a cohort in Immunoglobulin A nephropathy (IgAN) (n=1,376). Visit-to-visit variability in systolic blood pressure vs. Lowest quartile of visit-to-visit variability in systolic blood pressure was evaluated on Composite kidney disease progression events (50% decline in eGFR and kidney failure) (HR 2.12, 95% CI 1.31-3.44, p=<0.001). Higher visit-to-visit variability in systolic blood pressure was associated with an increased risk of kidney disease progression in patients with IgA nephropathy (HR 2.12; 95% CI 1.31-3.44).